PhRMA Blog
16 FOLLOWERS
PhRMA Blog is a platform for the Pharmaceutical Research and Manufacturers of America to share their perspective on the latest issues and trends in drug discovery and development. The blog covers a wide range of topics, from clinical trials to intellectual property, and provides a forum for industry leaders to share their insights and opinions.
PhRMA Blog
1w ago
USPTO’s findings confirm that assertions touted by patent critic groups that the patent system is broken and rampant with abuse are baseless ..read more
PhRMA Blog
1w ago
Election Day is less than two months away and voters are solidifying the issues they care about most this election and the solutions they want to see their elected officials focus on ..read more
PhRMA Blog
2w ago
A recent survey conducted by Magnolia Market Access provides insight directly from insurers, revealing in no uncertain terms that insurers plan to restrict coverage in Part D because of the Inflation Reduction Act (IRA). When assessing the law, the negative impact it is having on access to medicines cannot be overlooked ..read more
PhRMA Blog
2w ago
The unique American intellectual property (IP) system – including patent protections – promotes biopharmaceutical innovation and affordability, giving U.S. patients more medicine choices than anywhere else in the world. And medicine costs have remained a small and stable 14% share of health care spending that is on par with other countries ..read more
PhRMA Blog
2w ago
A new study on Alternative Funding Programs (AFPs), conducted by Leavitt Partners, found that AFPs threaten manufacturer Patient Assistance Programs (PAPs), programs intended to assist the uninsured or underinsured in accessing their medications ..read more
PhRMA Blog
2w ago
As we navigate another summer COVID surge and the upcoming flu season, now is the time to consult with your health care provider about vaccines for common respiratory viruses ..read more
Did the administration consider the value of innovative diabetes medicines in price setting process?
PhRMA Blog
2w ago
Throughout this first round of the price setting process under the Inflation Reduction Act, one concern keeps rising to the top: Is the administration factoring in feedback from patients and physicians when making pricing decisions ..read more
PhRMA Blog
1M ago
There has been increasing interest from some policymakers in Congress and the administration on terminal disclaimers and their use to resolve obviousness-type double patenting objections. Some proposed policies would even render entire patents unenforceable if a single claim in another patent is found invalid ..read more
PhRMA Blog
1M ago
Yesterday, the administration released the government-set prices for the first 10 medicines selected under the Inflation Reduction Act (IRA). The announcement left out important context about what is already happening in Medicare Part D because of the changes in the IRA and how Medicare patients are negatively impacted ..read more
PhRMA Blog
1M ago
Today marks the 59th anniversary of Medicaid, a state-administered program designed to ensure the most vulnerable in our communities can access the health care services they need ..read more